Please login to the form below

Not currently logged in

FDA approves Horizon's thyroid eye disease drug ahead of schedule

Horizon logoFirst FDA-approved treatment for rare autoimmune condition

UPDATED: J&J's $8bn Risperdal judgment reduced to $6.8m

Company will still appeal reduced verdict

EU grants conditional approval to Roche's lymphoma drug Polivy

RocheDrug demonstrated a 40% complete response rate in trial

Novartis gets EU approval for multiple sclerosis therapy Mayzent

Novartis buildingOffers subgroup of patients an important new treatment option

J&J wins another label expansion for Darzalex in Europe

Multiple myeloma treatment indicated for early use

J&J pushes to expand Imbruvica label after clinical success

JanssenEyes the frontline setting in chronic lymphocytic leukaemia

FDA delays decision on Intercept's NASH drug by three months

Action date pushed back to 26 June

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA webVerdict closely follows rejection of Nektar’s opioid analgesic

Brexit‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’

Brexit means pharma must review its intellectual property rights across Europe

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...